CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy.

Abstract

PURPOSE The aim of this study was to determine the value of CA 19-9 in therapy monitoring and follow-up of locally advanced pancreatic cancer treated by radiochemotherapy. MATERIALS AND METHODS Ninety-five patients with locally advanced irresectable adenocarcinoma of the pancreas were treated with hyperfractionated accelerated radiotherapy, with 44.8 Gy and 5-fluorouracil and folinic acid, January 1994 between and June 2001. CA 19-9 was measured before therapy, each week under therapy and every 4 weeks in the follow-up. RESULTS Median CA 19-9 before treatment was 420 U/ml. Patients with a level below the median had significantly better prognosis and a better treatment response than those above the median. In the follow-up CA 19-9 had a sensitivity of 100% in detection of recurrent disease with a specificity of 88. CONCLUSION CA 19-9 has a high prognostic value and may serve as an in vivo marker for treatment sensitivity. For detection of recurrent disease it shows a high sensitivity and specificity.

Statistics

0102030'04'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

77 Citations

Semantic Scholar estimates that this publication has 77 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Micke2003CA1I, title={CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy.}, author={Oliver Micke and Frank Bruns and Ulrich Sch{\"a}fer and Rene Kurowski and Eckehard Horst and Norman Willich}, journal={Anticancer research}, year={2003}, volume={23 2A}, pages={835-40} }